Company profile for GRIN Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

GRIN Therapeutics is dedicated to advancing research and development aimed at evaluating the safety and efficacy of the investigational therapy radiprodil. This promising treatment targets serious neurodevelopmental disorders, including GRIN-related disorders, tuberous sclerosis complex (TSC), and focal cortical dysplasia (FCD). Through rigorous clinical studies, we aim to offer hope and improved outcomes for individuals affec...
GRIN Therapeutics is dedicated to advancing research and development aimed at evaluating the safety and efficacy of the investigational therapy radiprodil. This promising treatment targets serious neurodevelopmental disorders, including GRIN-related disorders, tuberous sclerosis complex (TSC), and focal cortical dysplasia (FCD). Through rigorous clinical studies, we aim to offer hope and improved outcomes for individuals affected by these challenging conditions. Our commitment to innovation drives us to explore effective therapies that address unmet medical needs in neurodevelopmental health.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
230 Park Ave, Suite 2830, New York, NY 10169, United States
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

Global ChemShow

Not Confirmed

envelop Contact Supplier

Global ChemShow

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/grin-therapeutics-to-present-on-global-phase-3-beeline-clinical-trial-of-radiprodil-at-american-epilepsy-society-annual-meeting-302631358.html

PR NEWSWIRE
03 Dec 2025

https://www.prnewswire.com/news-releases/grin-therapeutics-presents-multiple-clinical-development-updates-for-radiprodil-at-2025-ilae-international-epilepsy-congress-302541483.html

PR NEWSWIRE
02 Sep 2025

https://www.prnewswire.com/news-releases/neurvati-neurosciences-and-grin-therapeutics-announce-appointment-of-gail-farfel-phd-to-their-boards-of-directors-302484310.html

PR NEWSWIRE
18 Jun 2025

https://www.biospace.com/deals/epilepsy-biotech-nabs-up-to-570m-in-deal-with-italys-angelini-plus-140m-fundraising

BIOSPACE
28 May 2025

https://www.prnewswire.com/news-releases/grin-therapeutics-and-angelini-pharma-enter-into-exclusive-collaboration-to-develop-and-commercialize-radiprodil-outside-north-america-302464677.html

PR NEWSWIRE
27 May 2025

https://www.prnewswire.com/news-releases/grin-therapeutics-receives-positive-opinion-for-eu-orphan-designation-for-radiprodil-for-treatment-of-grin-related-neurodevelopmental-disorder-302446917.html

PR NEWSWIRE
06 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty